In a crowded thyroid eye disease (TED) space, Innovent Biologics Inc. reported positive late-stage findings for its TED therapy, IBI-311, spurring the Suzhou, China-based biopharma to file for regulatory approval in China.
As investors continue to weigh VRDN-001’s chances against Tepezza (teprotumumab, Horizon Pharmaceuticals plc) in thyroid eye disease, Viridian Therapeutics Inc. popped the lid off positive preliminary data from the ongoing phase I/II trial with the intravenous full antagonist antibody to the insulin-like growth factor 1 receptor.
Less than two years old, Tourmaline Bio Inc. is gaining a public listing through a reverse merger with publicly traded Talaris Therapeutics Inc., as it enters a phase IIb with its lead IL-6 inhibitor for thyroid eye disease (TED).
Word that big pharma firms are sniffing around Horizon Therapeutics plc as a takeover candidate caused not only that firm’s shares to jump but also provided a boost for Viridian Therapeutics Inc., which has a thyroid eye disease (TED) candidate set to challenge Horizon’s Tepezza (teprotumumab-trbw), cleared by the U.S. FDA in January 2020.
Miragen Therapeutics Inc. gained ground lost on Wall Street earlier this month and then some, with shares (NASDAQ:MGEN) closing at $1.26, up 74 cents or 142% after the company disclosed plans to take over Viridian Therapeutics Inc., conducting at the same time a private placement that will raise $91 million.
New York-based Immunovant Inc.’s phase IIa results with neonatal Fc receptor (FcRn)-targeting IMVT-1401 in thyroid eye disease (TED), also known as Graves’ ophthalmopathy, prompted renewed speculation about the space, hot since the approval on Jan. 21 of Tepezza (teprotumumab-trbw) from Horizon Therapeutics plc, of Dublin.